Annovis Bio at CTAD 2026
Nov 16–19, 2026 Boston, MA ~1.7k attendees Website
Annovis Bio takes part in 3 sessions at CTAD 2026 in Boston. Its program centres on buntanetap, its oral drug that lowers production of neurotoxic proteins. Its work covers the design and baseline data of the pivotal trial in early Alzheimer's disease and predicting brain penetration of small-molecule drugs.
| Organization | CTAD 2026 Attendance |
|---|---|
Annovis Bio Malvern, Pennsylvania | |
Develops buntanetap, an oral small molecule that lowers production of neurotoxic proteins, in a pivotal trial in early Alzheimer's disease. | Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue |
Instantly find 20 buyers from Annovis Bio
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction